Receiver, Behind the Ear, In the Canal, In the Ear Aids are the best Product Type In Hearing AIDS.
Hearing AIDS is driven by the technological advancements in hearing aids, growing prevalence of hearing loss, and the increasing adoption of smart hearing aids due to the rising incidence of noise-induced hearing loss.
The emergence of the COVID-19 pandemic has changed the delivery of medical care across the world. The increased pressure due to the growing rate of hospitalization of COVID-19 patients had led to the re-profiling of many hospitals and departments for treating patients with COVID-19. Consequently, many elective surgeries were canceled or postponed worldwide to reserve or redirect the available limited capacities and resources (like hospital beds and patient care professionals) toward COVID-19 patient care.
The crisis has ushered in a new era in the hearing healthcare space that requires a radical rethinking of service delivery in audiology. Low- and no-touch services are now necessary for audiology patients (who are typically at the highest risk for COVID-19 morbidity and mortality due to their advanced age).
Also, hearing aid manufacturers have started focusing on including mobile audiometry and digital hearing care solutions for remote hearing aid device troubleshooting, counseling, fine-tuning, and tracking.
Globally, the rising incidence of hearing loss has made it extremely important to monitor and examine hearing functions. In children, untreated hearing loss negatively impacts language development, learning, and social engagement.
The high cost of hearing aids, such as cochlear implants and bone-anchored systems, is a major factor restraining the market growth, particularly in price-sensitive regions such as the Asia Pacific, Latin America, and Africa. Healthcare providers, especially in developing countries such as Brazil and Mexico, have low financial resources to invest in sophisticated technologies.
Extensive R&D activities are required to develop technologically advanced hearing aids. This results in a significant increase in the cost of manufacturing and the end price for customers. This makes associated surgical interventional procedures and diagnostic tests correspondingly expensive for patients.